Asia Pac ECM and Index Rebal, Shenton Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac ECM and Index Rebal

Asia Pac IPO & Placement Research, China Biotech

Shenton Research

Shenton Research is an independent Asia Pacific equity specialist. Our quantitative research covers index rebalancing flows, alongside exchange data analytics accross Asia Pacific. On the equity capital markets side, we focus on Asia Pacific ECM, especially biotech and TMT. Our lead analyst is frequently cited by international media.

Thematic (Sector/Industry)

<ul>
<li>China announced game approval for the September batch. The number of games approved is higher than in 2023 and 2024.</li>
<li>The pace of China game approval is above its pre-tightening level of August 2020 to July 2021.</li>
<li>Of the companies that we are monitoring, none got approval.</li>
</ul>


China announced game approval for the September batch. The number of games approved is higher than in 2023 and 2024.
The pace of China game approval is above its pre-tightening level of August 2020 to July 2021.
Of the companies that we are monitoring, none got approval.


Tencent/Netease: Two Months Without Approvals Despite Second-Highest Count Since 2022